희귀유전질환심포지엄조직위원회
Rare Genetic Disease Symposium Organizing Committee
PROFILE

박범준 교수/대표이사

PRG S&Tech and LCR in Past and present, and for Future world without rare genetic diseases
PRG S&Tech and the Laboratory of Cancer Research (LCR) at Pusan National University have developed three drug candidates undergoing clinical evaluation and are expanding research into other rare genetic diseases and rare cancers. A dedicated research institute is planned to connect patient needs with basic science, drug development, and treatment to advance personalized medicine.
부산대학교 분자생물학과/PRG S&Tech
EDUCATION
1995-1999, Ph.D. in Biology, Korea University
1993-1995, M.S. in Biology, Korea University
1989-1993, B.S. in Biology, Korea University
PROFESSIONAL EXPERIENCE
2017-Present, Chief Executive Officer, PRG S&Tech Inc.
2015-Present, Professor, Pusan National University
2014-2015, Visiting Scholar, The University of Texas MD Anderson Cancer Center
2010-2015, Associate Professor, Pusan National University
2006-2010, Assistant Professor, Pusan National University
2002-2006, Principal Researcher, Protein Enzyme Network Research Center, Seoul National University
2000-2002, Postdoctoral Researcher, National Institute of Health, Korea
1999-2000, Postdoctoral Researcher, Kyung Hee University
RESEARCH ACTIVITIES & OTHERS
-
SCI(E) Papers 87 in total(including 5 representative papers)
-
Disruption of nuclear-cytoskeletal linkage by Coil-1a LMNA mutations in Emery-Dreifuss Muscular Dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2026
-
Inhibition of SOD1 trimerization is a novel drug target for ALS disease. Translational Neurodegeneration, 2025
-
Therapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor, Neuro-Oncology, 2024
-
The Therapeutic effect through DX2 inhibition in nicotine-induced lung cancer progression, Molecular Therapy Oncology, 2024
-
Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype, Journal Of Clinical Investigation, 2016